Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084684" target="_blank" >RIV/00023001:_____/24:00084684 - isvavai.cz</a>
Alternative codes found
RIV/68407700:21460/24:00382316 RIV/00216208:11110/24:10480188
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fcvm.2024.1343775/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fcvm.2024.1343775/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fcvm.2024.1343775" target="_blank" >10.3389/fcvm.2024.1343775</a>
Alternative languages
Result language
angličtina
Original language name
Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration
Original language description
Background Myasthenia gravis is a rare chronic autoimmune neuromuscular disorder mainly caused by autoantibodies to the nicotinic acetylcholine receptor. Cholesterol is an essential molecule that affects the distribution and proper functioning of this receptor. Several reports have described the potential worsening of myasthenia gravis in patients treated with statins.Case presentation The patient was an obese 72 years old man, past smoker, diagnosed with ischaemic heart disease, type 2 diabetes mellitus and lipid metabolism disorder. Statin treatment was not implemented because of chronic myasthenia gravis and PCSK9i monotherapy [Repatha (evolucamab), 140 mg] was implemented to treat dyslipidaemia. Within 24 h after the first dose of PCSK9i the patient developed severe muscle weakness, joint pain, fever, and general discomfort, lasting for several days. Despite strong advice against the second dose administration, this was self-administered approximately 2 weeks later, leading to report significant worsening of the muscle problems, leading to the patient admittion to the neurology department where he was being treated for myasthenia gravis attack.Conclusion Based on the neurologist's conclusion, it can be assumed that in this case, treatment with PCSK9i resulted in significant worsening of the patient's chronic disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in cardiovascular medicine
ISSN
2297-055X
e-ISSN
2297-055X
Volume of the periodical
11
Issue of the periodical within the volume
March 12
Country of publishing house
CH - SWITZERLAND
Number of pages
4
Pages from-to
"art. no. 1343775"
UT code for WoS article
001190363600001
EID of the result in the Scopus database
2-s2.0-85188521325